Cargando…

l-Dopa and Brain Serotonin System Dysfunction

l-dopa is used to treat the motor symptoms associated with Parkinson’s disease, a neurodegenerative movement disorder characterized by a loss of dopamine neurons. l-dopa is the precursor to dopamine and crosses the blood-brain barrier to increase dopamine neurotransmission. This review will focus on...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stansley, Branden J., Yamamoto, Bryan K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5634697/ https://www.ncbi.nlm.nih.gov/pubmed/29056652 http://dx.doi.org/10.3390/toxics3010075

Ejemplares similares

A comparative review of cell culture systems for the study of microglial biology in Alzheimer’s disease
por: Stansley, Branden, et al.
Publicado: (2012)

L-DOPA
por: Hornykiewicz, Oleh
Publicado: (2017)

Serotonin System Implication in l-DOPA-Induced Dyskinesia: From Animal Models to Clinical Investigations
por: Carta, Manolo, et al.
Publicado: (2014)

Opioid system in L-DOPA-induced dyskinesia
por: Pan, Jing, et al.
Publicado: (2017)

Role of Serotonin Neurons in L-DOPA- and Graft-Induced Dyskinesia in a Rat Model of Parkinson's Disease
por: Shin, Eunju, et al.
Publicado: (2012)

L-Dopa and Behavior
por: Kebabian, John
Publicado: (1974)

Palmitoyl Serotonin Inhibits L-dopa-induced Abnormal Involuntary Movements in the Mouse Parkinson Model
por: Park, Hye-Yeon, et al.
Publicado: (2016)

Mass spectrometry imaging identifies abnormally elevated brain l-DOPA levels and extrastriatal monoaminergic dysregulation in l-DOPA–induced dyskinesia
por: Fridjonsdottir, Elva, et al.
Publicado: (2021)

L-DOPA-therapy in Parkinson’s disease: some personal reflections on L-DOPA therapy from Vienna and Berlin
por: Riederer, Peter, et al.
Publicado: (2023)

L-Dopa and the Albino Riddle: Content of L-Dopa in the Developing Retina of Pigmented and Albino Mice
por: Roffler-Tarlov, Suzanne, et al.
Publicado: (2013)

L-DOPA in Parkinson’s Disease: Looking at the “False” Neurotransmitters and Their Meaning
por: Chagraoui, Abdeslam, et al.
Publicado: (2019)

Pathophysiological Mechanisms and Experimental Pharmacotherapy for L-Dopa-Induced Dyskinesia
por: Fabbrini, Andrea, et al.
Publicado: (2021)

Parkinson’s disease, L-DOPA, and endogenous morphine: A revisit
por: Stefano, George B., et al.
Publicado: (2012)

Herbs containing L- Dopa: An update
por: Ramya, Kuber B, et al.
Publicado: (2007)

Advances in the automated synthesis of 6-[(18)F]Fluoro-L-DOPA
por: Neves, Ângela C. B., et al.
Publicado: (2021)

L-DOPA Uptake in Astrocytic Endfeet Enwrapping Blood Vessels in Rat Brain
por: Inyushin, M. Y., et al.
Publicado: (2012)

Corticostriatal Plastic Changes in Experimental L-DOPA-Induced Dyskinesia
por: Ghiglieri, Veronica, et al.
Publicado: (2012)

Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson’s Disease
por: Bello, Fabio Del, et al.
Publicado: (2019)

On the neuronal circuitry mediating l-DOPA-induced dyskinesia
por: Cenci, M. Angela, et al.
Publicado: (2018)

Genetic Variation in the Human Brain Dopamine System Influences Motor Learning and Its Modulation by L-Dopa
por: Pearson-Fuhrhop, Kristin M., et al.
Publicado: (2013)

Readiness Potential in Parkinson's Disease: Effects of L-Dopa Therapy and Brain Transplants
por: Martínez, D. N. Velázquez, et al.
Publicado: (1992)

Betalain production is possible in anthocyanin-producing plant species given the presence of DOPA-dioxygenase and L-DOPA
por: Harris, Nilangani N, et al.
Publicado: (2012)

Interaction of Human Dopa Decarboxylase with L-Dopa: Spectroscopic and Kinetic Studies as a Function of pH
por: Montioli, Riccardo, et al.
Publicado: (2013)

L-DOPA Is an Endogenous Ligand for OA1
por: Lopez, Vanessa M, et al.
Publicado: (2008)

Electroanalytical Overview: The Determination of Levodopa (L-DOPA)
por: Crapnell, Robert D., et al.
Publicado: (2023)

Striatal Astrocytes Act as a Reservoir for L-DOPA
por: Asanuma, Masato, et al.
Publicado: (2014)

Radiation-induced Brain Calcification Leads to L-dopa-resistant Parkinsonism and Cerebellar Ataxia
por: Shimada, Tomoyo, et al.
Publicado: (2022)

Genomics Analysis of L-DOPA Exposure in Drosophila sechellia
por: Lanno, Stephen M., et al.
Publicado: (2019)

Myocardial Metastases on 6-[(18)F] fluoro-L-DOPA PET/CT: A Retrospective Analysis of 116 Serotonin Producing Neuroendocrine Tumour Patients
por: Noordzij, Walter, et al.
Publicado: (2014)

T39. NEURAL MECHANISMS OF METABOTROPIC GLUTAMATE RECEPTOR 3 MEDIATED ENHANCEMENT OF SYNAPTIC PLASTICITY AND COGNITION
por: Stansley, Branden, et al.
Publicado: (2018)

43.1 GENETIC INSIGHTS LEAD TO DISCOVERY OF SELECTIVE ACTIVATORS OF MGLU1 AND MGLU3 METABOTROPIC GLUTAMATE RECEPTORS AS POTENTIAL TREATMENTS FOR SCHIZOPHRENIA
por: Conn, P Jeffrey, et al.
Publicado: (2018)

Imbalanced Dopaminergic Transmission Mediated by Serotonergic Neurons in L-DOPA-Induced Dyskinesia
por: Navailles, Sylvia, et al.
Publicado: (2012)

Dopamine D3 Receptor Plasticity in Parkinson’s Disease and L-DOPA-Induced Dyskinesia
por: Lanza, Kathryn, et al.
Publicado: (2021)

Management of L-dopa overdose in the competitive inhibition state
por: Hinz, Marty, et al.
Publicado: (2014)

Molecular Effects of L-dopa Therapy in Parkinson’s Disease
por: Dorszewska, Jolanta, et al.
Publicado: (2014)

Maladaptive Synaptic Plasticity in L-DOPA-Induced Dyskinesia
por: Wang, Qiang, et al.
Publicado: (2016)

Beyond L-DOPA: hope for Parkinson’s treatment and diagnosis
Publicado: (2017)

Metabolic engineering of tomato fruit enriched in L-DOPA
por: Breitel, Dario, et al.
Publicado: (2021)

Circuit Mechanisms of L-DOPA-Induced Dyskinesia (LID)
por: Yang, Kai, et al.
Publicado: (2021)

An Integrative Approach to Treat Parkinson's Disease: Ukgansan Complements L-Dopa by Ameliorating Dopaminergic Neuronal Damage and L-Dopa-Induced Dyskinesia in Mice
por: Huh, Eugene, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_8is74d5pboon6128foqtgi2m2g